Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Evaluating the Prevalence of the KIT D816V Mutation in Peripheral Blood of Patients With Evidence of Systemic Mast Cell Activation (MCA)

NCT04811365 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.

NCT NCT04811365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04811365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Evaluating the Prevalence of the KIT D816V Mutation in Peripheral Blood of Patients With Evidence of Systemic Mast Cell Activation (MCA)
Lead sponsor
Blueprint Medicines Corporation
Phase
Observational
Overall status
Completed
Start date
June 29, 2021
Completion date
March 31, 2023
Enrollment
379 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

kit d816v mutation, systemic mast cell activation